Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysosome-autophagosome fusion, regulated by the MTORC1 pathway, is a critical step in autophagy, enabling the degradation and recycling of cellular components. Active MTORC1, stimulated by nutrient availability, inhibits autophagy initiation and lysosomal function. Conversely, MTORC1 inactivation promotes autophagy. The fusion process involves Rab GTPases, SNARE proteins, tethering factors, and phosphoinositides. Dysregulation is implicated in various diseases, highlighting the importance of controlled autophagy.
Varies depending on the specific intervention; MTOR inhibitors promote autophagy by de-repressing ULK1/2 and TFEB. Lysosomotropic agents disrupt lysosomal pH and function, impairing autophagic degradation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosome-Autophagosome Fusion via MTORC1 Pathway (N/A).